Close this search box.

Clinical Trial: ECOG-ACRIN E4512


Status: Closed

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

E4512 is closed to accrual, effective May 10, 2024.